Patents by Inventor Richard Brokx

Richard Brokx has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • LILRB1 AND LILRB2-BINDING MOLECULES AND USES THEREFOR
    Publication number: 20240150462
    Abstract: The invention provides novel anti-LILR antibodies, pharmaceutical compositions comprising such antibodies, and therapeutic methods of using such antibodies and pharmaceutical compositions for the treatment of diseases such as cancer, autoimmune disease, or allergic inflammation.
    Type: Application
    Filed: March 11, 2022
    Publication date: May 9, 2024
    Inventors: Richard BROKX, Jacqueline M. MASON, Mark Robert BRAY, Gordon S. DUNCAN
  • TSG-6 ANTIBODIES AND USES THEREFOR
    Publication number: 20220153834
    Abstract: The invention provides novel anti-TSG-6 antibodies, pharmaceutical compositions comprising such antibodies, and therapeutic methods of using such antibodies and pharmaceutical compositions for the treatment of diseases such as cancer or autoimmune disease.
    Type: Application
    Filed: March 11, 2020
    Publication date: May 19, 2022
    Inventors: Richard Brokx, Jacqueline M. Mason, Mark R. Bray
  • LILRB3-BINDING MOLECULES AND USES THEREFOR
    Publication number: 20220089723
    Abstract: The invention provides novel anti-LILRB3 antibodies, pharmaceutical compositions comprising such antibodies, and therapeutic methods of using such antibodies and pharmaceutical compositions for the treatment of diseases such as cancer, autoimmune disease, or allergic inflammation This invention can also be used to modulate osteoclast differentiation.
    Type: Application
    Filed: January 16, 2020
    Publication date: March 24, 2022
    Inventors: Richard Brokx, Jacqueline M. Mason, Mark R. Bray
  • FCMR-Binding Molecules and Uses Thereof
    Publication number: 20220089725
    Abstract: The invention provides novel anti-FCMR antibodies, pharmaceutical compositions comprising such antibodies, and therapeutic methods of using such antibodies and pharmaceutical compositions for the treatment of diseases such as cancer or autoimmune disease.
    Type: Application
    Filed: February 14, 2020
    Publication date: March 24, 2022
    Inventors: Richard Brokx, Jacqueline M. Mason, Mark R. Bray
  • RIPK2 INHIBITORS AND METHOD OF TREATING CANCER WITH SAME
    Publication number: 20210261554
    Abstract: The invention is a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. Values for the variables are provided herein. Also included is a pharmaceutical composition comprising the compound represented by Structural Formula (I) and a pharmaceutically acceptable carrier or diluent and methods of treating a subject with cancer with the compound of Structural Formula (I).
    Type: Application
    Filed: December 26, 2020
    Publication date: August 26, 2021
    Inventors: Radoslaw Laufer, Grace Ng, Richard Brokx, Heinz W. Pauls, Sze-Wan Li, Jacqueline M. Mason, Mark R. Bray
  • RIPK2 inhibitors and method of treating cancer with same
    Patent number: 10875863
    Abstract: The invention is a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. Values for the variables are provided herein. Also included is a pharmaceutical composition comprising the compound represented by Structural Formula (I) and a pharmaceutically acceptable carrier or diluent and methods of treating a subject with cancer with the compound of Structural Formula (I).
    Type: Grant
    Filed: January 28, 2019
    Date of Patent: December 29, 2020
    Assignee: UNIVERSITY HEALTH NETWORK
    Inventors: Radoslaw Laufer, Grace Ng, Richard Brokx, Heinz W. Pauls, Sze-Wan Li, Jacqueline M. Mason, Mark R. Bray
  • RIPK2 INHIBITORS AND METHOD OF TREATING CANCER WITH SAME
    Publication number: 20190225617
    Abstract: The invention is a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. Values for the variables are provided herein. Also included is a pharmaceutical composition comprising the compound represented by Structural Formula (I) and a pharmaceutically acceptable carrier or diluent and methods of treating a subject with cancer with the compound of Structural Formula (I).
    Type: Application
    Filed: January 28, 2019
    Publication date: July 25, 2019
    Inventors: Radoslaw Laufer, Grace Ng, Richard Brokx, Heinz W. Pauls, Sze-Wan Li, Jacqueline M. Mason, Mark R. Bray
  • RIPK2 inhibitors and method of treating cancer with same
    Patent number: 10239881
    Abstract: The invention is a compound represented by Structural Formula (I): (I); or a pharmaceutically acceptable salt thereof. Values for the variables are provided herein. Also included is a pharmaceutical composition comprising the compound represented by Structural Formula (I) and a pharmaceutically acceptable carrier or diluent and methods of treating a subject with cancer with the compound of Structural Formula (I).
    Type: Grant
    Filed: October 9, 2015
    Date of Patent: March 26, 2019
    Assignee: University Health Network
    Inventors: Radoslaw Laufer, Grace Ng, Richard Brokx, Heinz W. Pauls, Sze-wan Li, Jacqueline M. Mason, Mark R. Bray
  • RIPK2 INHIBITORS AND METHOD OF TREATING CANCER WITH SAME
    Publication number: 20180282335
    Abstract: The invention is a compound represented by Structural Formula (I): (I); or a pharmaceutically acceptable salt thereof. Values for the variables are provided herein. Also included is a pharmaceutical composition comprising the compound represented by Structural Formula (I) and a pharmaceutically acceptable carrier or diluent and methods of treating a subject with cancer with the compound of Structural Formula (I).
    Type: Application
    Filed: October 9, 2015
    Publication date: October 4, 2018
    Inventors: Radoslaw Laufer, Grace Ng, Richard Brokx, Heinz W. Pauls, Sze-wan Li, Jacqueline M. Mason, Mark R. Bray